Yantai LNC Biotechnology
Yantai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $450M
Overview
A clinical-stage biotech developing innovative radiopharmaceuticals for cancer theranostics, backed by Dongcheng Pharmaceutical Group.
Oncology
Technology Platform
Integrated theranostic platform for radiopharmaceuticals featuring proprietary pharmacokinetic optimization technologies and a dual-target drug development platform for creating paired diagnostic and therapeutic agents.
Opportunities
The global radiopharmaceutical therapeutics market is experiencing significant growth, driven by recent FDA approvals.
LNC is well-positioned to capture share in the large Chinese oncology market and expand in Asia through its Singapore subsidiary and robust IP portfolio.
Risk Factors
As a pre-revenue company, LNC faces clinical development risks, including potential trial failures for its lead candidates.
The radiopharmaceutical space is becoming increasingly competitive, and the company must successfully navigate complex manufacturing, logistics, and regulatory pathways for radioactive drugs.
Competitive Landscape
LNC competes with global pharma (e.g., Novartis) and biotechs in radiopharmaceuticals. Its differentiation is its integrated theranostic platform, focus on multiple targets (PSMA, FAP, αvβ3), and strategic backing from Dongcheng's established nuclear medicine ecosystem in China.